Neuroprotective effect of glycine in the acute period of ischemic stroke

Zhurnal Nevropatolgii i Psikhiatrii im. S S Korsakova

Volumn 99, Issue 2, 1999, Pages 12-20

  Gusev, E I ^a   Skvortsova, V I ^a   Komissarova, I A ^a   Dambinova, S A ^a   Raevsky, K S ^a   Alekseev, A A ^a   Bashkatova, V G ^a   Kovalenko, A V ^a   Kudrin, V S ^a   Yakovleva, E V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; LIPID PEROXIDATION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; SUBLINGUAL DRUG ADMINISTRATION; TIME;

ACUTE DISEASE; ADMINISTRATION, SUBLINGUAL; ADULT; AGED; AUTOANTIBODIES; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; GLYCINE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0032601810     PISSN: 00444588     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Beaughard M., Michelin M., Massingham R. J. Krieglstein, H. Oberpichler (eds) Pharmacology of Cerebral Ischemia. Stuttgart 1990; 275-280.
2. Buchan A., Hui L., Pulsinelli W.A. J Neurosci 1991; 11: 1049.
3. Carter A.J. Drugs Future 1992; 17: 595-613.
4. Castillo J., Davalos A., Noya M. Lancet 1997; 349: 79-83.
5. Chizhmakov I.V., Kishin N.I., Krishtal O.A., Tsyndrenko A.Y. Neurosci Lett 1989; Apr 24: 99: 1-2: 131-136.
6. Croucher M.J., Bradford H.F. Brain Res 1991; 543: 91-96.
7. Dambinova S.A. Eur Patent Bull 1993; 93/69 WO 93/00586.
8. Davalos A., Naveiro J., Noya M. Stroke 1996; 27: 1060-1065.
9. Fagg G.E., Foster A.C. Neurosci 1983; 9: 4: 701-719.
10. Fisher M.A. J Cerebrovasc Dis 1991; 1: 1: 112-119.
11. Ginsberg M. D., Globus M.Y.-T., Busto R., Dietrich W.D. J. Krieglstein, H. Oberpichler (eds). Pharmacology of Cerebral Ischemia. Stuttgart 1990; 499-510.
12. Giroux C., Scatton B. Eur Neurol 1996; 36: 2: 61-64.
13. Granger C. V., Hamilton B.R., Gresham G.E., Kramer A.A. Arch Phys Med Rehabil 1989; 70: 100-103.
14. Gusev E.I., Skvortsova V.I., Raevskiy K.S. et al. Eur J Neurol 1997; 4: 1: 152/78.
15. Henderson G., Johnson J., Ascher P. J Physiol 1990; 430: 189-212.
16. James T.A., Starr M.S. Eur J Pharmacol 1979; 57: 115-125.
17. Johnson J.W., Ascher P. Nature 1987; 325: 529-531.
18. Jones M.G., Szatkowski M.S. Neurosci Lett 1995; Dec 15: 201: 3: 227-230.
19. Kemp J.A., Leeson P.D. Trends Pharmacol Sci 1993; 14: 20-25.
20. Kleckner N.W., Dingledine R. Science 1988; 24: 835.
21. Komissarova I.A., Gudkova Ju.V., Soldatenkova T.D. et al. Patent Bull Russian Federation 1992; No 2025124.
22. Lapin I.P. Eur J Pharmacol 1981; 71: 495-498.
23. Loscher W., Wlaz P., Rundfeldt C. et al. Br J Pharmacol 1994; 112: 97-106.
24. Mahoney F.I., Barthel D.W. Md State Med J 1965; 14: 61-65.
25. Mayor F., Valdivieso F., Ugar M. J Amino Acid Neurotransmitters Advanced in Biochem Psychopharm 1991; 29: 551-560
26. Meister A. Biochemistry of the Amino Acids. New York 1957.
27. Obrenovitch T.P., Urenjak J., Zilkha E. Br J Pharmacol 1994 Dec; 113: 4: 1295-1302.
28. Obrenovitch T.P., Hardy A.M., Urenjak J. Brain Res 1997; Jan 23: 746: 1-2: 190-194.
29. Ohkawa H., Ohisi N., Yagi K. Analyt Biochem 1995; 95: 351-355.
30. O'Neill M., Allain H., Bentue-Ferrer D. et al. Eur Neurol 1995; 35: 1: 28-36.
31. Orgogozo J.M., Dartigues J.F. N. Battistini et al. (eds). Acute Brain Ischemia. Medical and Surgical Therapy. New York 1986; 282-289.
32. Patel J., Zinkand W.C., Thompson C. et al. Neurochem 1990; 54: 849-854.
33. Peterson S.L., Boehnke L.E. 1989; 104: 113-117.
34. Peterson S.L. Eur J Pharmacol 1991; 199: 341-348.
35. Peterson S.L., Schwade N.D. Epilepsy Res 1993; 15: 141-148.
36. Priestley T., Home A.L., McKernan R.M., Kemp J.A. Brain Res 1990; 531: 183-188.
37. Romanova G.A., Kudrin V.S., Malikova L.A. Pharmacol Res 1995; 31: 128.
38. Scandinavian Stroke Study Group Stroke 1985; 16: 885-890.
39. Scheinberg P. Neurology 1991; 41: 1867-1873.
40. Scolnick P., Marvizon J., Jackson B. et al. Life Sci 1989; 45: 1647-1655.
41. Silver B., Weber J., Fisher M. Clin Neuropharmacol 1996; 19: 2: 101-128.
42. Stark L., Peterson S.L., Ablertson T.E. (Ed.) J.A. Wada. Kindling 4. New York 1990; 267-281.
43. Thomson A.M. Prog Neurobiol 1990; 35: 53-74.
44. Toth E., Lajtha A., Sarhan S., Seiler N. Neurochem Res 1983; 8: 291-302.
45. Trikclebank M.D., Saywell K. Soc Neurosci Abstr 1990; 16: 462.
46. Von Lubitz D.K.J.E., Lin R.C.-S., McKenzie R.J. et al. Eur J Pharmacol 1992; 219: 153-158.
47. Williams R. R. Dernfeld (ed.) Biogenesis of natural compounds. New York 1963; 368-404.